JP2019513346A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513346A5 JP2019513346A5 JP2018545438A JP2018545438A JP2019513346A5 JP 2019513346 A5 JP2019513346 A5 JP 2019513346A5 JP 2018545438 A JP2018545438 A JP 2018545438A JP 2018545438 A JP2018545438 A JP 2018545438A JP 2019513346 A5 JP2019513346 A5 JP 2019513346A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- idiotype antibody
- antibody
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 24
- 230000003302 anti-idiotype Effects 0.000 claims 22
- 102000009027 Albumins Human genes 0.000 claims 7
- 108010088751 Albumins Proteins 0.000 claims 7
- 239000008280 blood Substances 0.000 claims 7
- 210000004369 blood Anatomy 0.000 claims 7
- 230000004927 fusion Effects 0.000 claims 5
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 238000001962 electrophoresis Methods 0.000 claims 2
- 238000011156 evaluation Methods 0.000 claims 2
- 101710085938 Matrix protein Proteins 0.000 claims 1
- 101710127721 Membrane protein Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022015613A JP7331168B2 (ja) | 2016-03-04 | 2022-02-03 | 多発性骨髄腫におけるｍタンパク質反応の臨床評価 |
| JP2023129240A JP7557023B2 (ja) | 2016-03-04 | 2023-08-08 | 多発性骨髄腫におけるｍタンパク質反応の臨床評価 |
| JP2024157490A JP7835815B2 (ja) | 2016-03-04 | 2024-09-11 | 多発性骨髄腫におけるｍタンパク質反応の臨床評価 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16158714.2 | 2016-03-04 | ||
| EP16158714 | 2016-03-04 | ||
| PCT/EP2017/055011 WO2017149122A1 (en) | 2016-03-04 | 2017-03-03 | Clinical assessment of m-protein response in multiple myeloma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022015613A Division JP7331168B2 (ja) | 2016-03-04 | 2022-02-03 | 多発性骨髄腫におけるｍタンパク質反応の臨床評価 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019513346A JP2019513346A (ja) | 2019-05-30 |
| JP2019513346A5 true JP2019513346A5 (enExample) | 2020-04-02 |
| JP7362250B2 JP7362250B2 (ja) | 2023-10-17 |
Family
ID=55745535
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018545438A Active JP7362250B2 (ja) | 2016-03-04 | 2017-03-03 | 多発性骨髄腫におけるｍタンパク質反応の臨床評価 |
| JP2022015613A Active JP7331168B2 (ja) | 2016-03-04 | 2022-02-03 | 多発性骨髄腫におけるｍタンパク質反応の臨床評価 |
| JP2023129240A Active JP7557023B2 (ja) | 2016-03-04 | 2023-08-08 | 多発性骨髄腫におけるｍタンパク質反応の臨床評価 |
| JP2024157490A Active JP7835815B2 (ja) | 2016-03-04 | 2024-09-11 | 多発性骨髄腫におけるｍタンパク質反応の臨床評価 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022015613A Active JP7331168B2 (ja) | 2016-03-04 | 2022-02-03 | 多発性骨髄腫におけるｍタンパク質反応の臨床評価 |
| JP2023129240A Active JP7557023B2 (ja) | 2016-03-04 | 2023-08-08 | 多発性骨髄腫におけるｍタンパク質反応の臨床評価 |
| JP2024157490A Active JP7835815B2 (ja) | 2016-03-04 | 2024-09-11 | 多発性骨髄腫におけるｍタンパク質反応の臨床評価 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US11618789B2 (enExample) |
| EP (1) | EP3423498A1 (enExample) |
| JP (4) | JP7362250B2 (enExample) |
| KR (1) | KR102427948B1 (enExample) |
| CN (1) | CN108699161B (enExample) |
| AU (2) | AU2017226960B2 (enExample) |
| IL (2) | IL260750B2 (enExample) |
| SG (1) | SG11201806214RA (enExample) |
| WO (1) | WO2017149122A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019209730A1 (en) | 2018-04-24 | 2019-10-31 | Helena Laboratories Corporation | Removal of interfering factors from serum protein electrophoresis profiles |
| WO2020052546A1 (zh) | 2018-09-11 | 2020-03-19 | 江苏恒瑞医药股份有限公司 | 抗cd38抗体、其抗原结合片段及医药用途 |
| JP7687956B2 (ja) | 2019-03-15 | 2025-06-03 | モルフォシス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 自己抗体介在性自己免疫疾患の処置のための、抗ｃｄ３８抗体及びその医薬組成物 |
| WO2023094696A1 (en) * | 2021-11-29 | 2023-06-01 | Morphosys Ag | Methods for reducing anti-cd38 mab drug interference in serological assays |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3912610A (en) * | 1974-07-23 | 1975-10-14 | Icl Scient | Method for electroquantitative determination of proteins |
| US4102990A (en) * | 1977-12-05 | 1978-07-25 | General Electric Company | Electrophoretic assay for antigen-antibody reaction based on particle-particle coupling |
| US4661586A (en) | 1981-11-17 | 1987-04-28 | The Board Of Trustees Of The Leland Stanford Junior University | Monoclonal anti-idiotype antibodies |
| US4578350A (en) * | 1983-09-23 | 1986-03-25 | Syntex (U.S.A.) Inc. | Immunoassays employing protected labels |
| US6936464B1 (en) * | 1992-10-02 | 2005-08-30 | Cancer Research Technology Limited | Immune responses to fusion proteins |
| US20020164788A1 (en) | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
| JP2003524587A (ja) | 1998-06-05 | 2003-08-19 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | 多発性骨髄腫を処置するための、ｃｄ３８に対する、遺伝子操作した抗体の使用 |
| EP1174440A1 (en) | 2000-07-19 | 2002-01-23 | U-BISys B.V. | A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment |
| US7348139B1 (en) * | 2001-04-13 | 2008-03-25 | The Johns Hopkins University School Of Medicine | SOCS-1 gene methylation in cancer |
| US6902669B2 (en) | 2002-09-13 | 2005-06-07 | Fleetguard, Inc. | Filter cartridge with floating seal |
| EP1544215A1 (en) | 2003-12-17 | 2005-06-22 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Human anti-idiotypic antibody fragments that mimic HER-2/neu |
| ES2541436T3 (es) | 2004-02-06 | 2015-07-20 | Morphosys Ag | Anticuerpos humanos anti-CD38 y usos para ellos |
| AU2005235811B2 (en) * | 2004-02-06 | 2011-11-03 | Morphosys Ag | Anti-CD38 human antibodies and uses therefor |
| HUE025945T2 (en) * | 2005-02-15 | 2016-07-28 | Univ Duke | Anti-CD19 antibodies and their applications in oncology |
| EP3312196B1 (en) * | 2005-03-23 | 2019-07-17 | Genmab A/S | Antibodies against cd38 for treatment of multiple myeloma |
| EP1888647A2 (en) | 2005-05-24 | 2008-02-20 | MorphoSys AG | Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38 |
| PL2860192T3 (pl) | 2005-10-12 | 2018-03-30 | Morphosys Ag | Wytwarzanie i profilowanie w pełni ludzkich, uzyskanych z HuCAL GOLD terapeutycznych przeciwciał swoistych wobec ludzkiego CD38 |
| AU2007258609B2 (en) * | 2006-06-07 | 2013-01-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20080066739A1 (en) * | 2006-09-20 | 2008-03-20 | Lemahieu Edward | Methods and systems of delivering medication via inhalation |
| US9382327B2 (en) * | 2006-10-10 | 2016-07-05 | Vaccinex, Inc. | Anti-CD20 antibodies and methods of use |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| CA2696210A1 (en) * | 2007-08-28 | 2009-03-12 | Abbott Biotechnology Ltd. | Compositions and methods comprising binding proteins for adalimumab |
| WO2010002911A2 (en) * | 2008-06-30 | 2010-01-07 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Methods and materials for monitoring myeloma using quantitative mass spetrometry |
| EP2580243B1 (en) | 2010-06-09 | 2019-10-16 | Genmab A/S | Antibodies against human cd38 |
| NZ607473A (en) * | 2010-09-27 | 2014-11-28 | Morphosys Ag | Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl |
| AU2011307251A1 (en) | 2010-09-30 | 2013-02-28 | Merck Sharp & Dohme Corp. | Generation, characterization and uses thereof of anti-HER3 antibodies |
| JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| AU2013237894B2 (en) | 2012-03-30 | 2018-06-21 | The Board Of Regents Of The University Of Oklahoma | High molecular weight heparosan polymers and methods of production and use thereof |
| ES2658953T3 (es) * | 2012-09-25 | 2018-03-13 | Morphosys Ag | Combinaciones y usos de los mismos |
| CA2909952C (en) | 2013-04-29 | 2021-10-12 | Teva Pharmaceuticals Australia Pty Ltd. | Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b |
| EP3063173B1 (en) | 2013-10-31 | 2020-07-29 | Sanofi | Specific anti-cd38 antibodies for treating human cancers |
| AU2015216875B2 (en) * | 2014-02-14 | 2021-02-25 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
-
2017
- 2017-03-03 CN CN201780014944.6A patent/CN108699161B/zh active Active
- 2017-03-03 EP EP17708766.5A patent/EP3423498A1/en active Pending
- 2017-03-03 SG SG11201806214RA patent/SG11201806214RA/en unknown
- 2017-03-03 KR KR1020187026496A patent/KR102427948B1/ko active Active
- 2017-03-03 IL IL260750A patent/IL260750B2/en unknown
- 2017-03-03 JP JP2018545438A patent/JP7362250B2/ja active Active
- 2017-03-03 US US16/080,870 patent/US11618789B2/en active Active
- 2017-03-03 IL IL305540A patent/IL305540B2/en unknown
- 2017-03-03 AU AU2017226960A patent/AU2017226960B2/en active Active
- 2017-03-03 WO PCT/EP2017/055011 patent/WO2017149122A1/en not_active Ceased
-
2022
- 2022-02-03 JP JP2022015613A patent/JP7331168B2/ja active Active
-
2023
- 2023-02-14 US US18/168,930 patent/US20230203189A1/en not_active Abandoned
- 2023-08-08 JP JP2023129240A patent/JP7557023B2/ja active Active
-
2024
- 2024-03-07 AU AU2024201503A patent/AU2024201503A1/en active Pending
- 2024-08-13 US US18/802,877 patent/US20240392034A1/en active Pending
- 2024-09-11 JP JP2024157490A patent/JP7835815B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020536488A5 (enExample) | ||
| JP2021500916A5 (enExample) | ||
| JP2018536393A5 (enExample) | ||
| JP2017508475A5 (enExample) | ||
| PH12020551012A1 (en) | Monoclonal antibodies and methods for using same | |
| EA201891435A1 (ru) | Гуманизированные моноклональные антитела, моноклональные антитела мыши или химерные моноклональные антитела против cd47 | |
| AR084210A1 (es) | PROTEINAS DE UNION AL TNF-a | |
| JP2019528038A5 (enExample) | ||
| FI3332006T3 (fi) | Uusia anti-PD-L1-vasta-aineita | |
| JP2018021031A5 (enExample) | ||
| JP2014512809A5 (enExample) | ||
| CO6231038A2 (es) | Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos | |
| EA201792221A1 (ru) | Антитела против сортилина и способы их применения | |
| JOP20210168A1 (ar) | أجسام مضادة أحادية النسيلة ترتبط نوعيًا مع trbv9 بشري | |
| NZ716369A (en) | Anti-ox40 antibodies and methods of using the same | |
| JP2012143232A5 (enExample) | ||
| JOP20210169B1 (ar) | أجسام مضادة أحادية النسيلة ضد منطقة سلسلة بيتا من trbv9 بشري | |
| HRP20200034T1 (hr) | Monoklonska protutijela protiv čimbenika rasta i diferencijacije 15 (gdf-15), te njihova upotreba u liječenju kaheksije uzrokovane rakom i raka | |
| RU2017113732A (ru) | Антитело, которое обладает способностью нейтрализовать субстанцию, обладающую активностью, альтернативной функции фактора свертывания viii (fviii) | |
| RU2011121818A (ru) | Способ иммунологического анализа белка cxcl1 человека | |
| RU2014127287A (ru) | Антитела, используемые для пассивной вакцинации против гриппа | |
| JP2018515071A5 (enExample) | ||
| EA201391453A1 (ru) | Новое антитело против рецептора il-23 человека | |
| JP2022058881A (ja) | 多発性骨髄腫におけるｍタンパク質反応の臨床評価 | |
| RU2016151730A (ru) | Антитела для лабораторной диагностики концентрации интерлейкина-11 |